Lilly Launches Byetta In China To Target World's Second Largest Diabetes Market

SHANGHAI - Eli Lilly announced Aug. 23 that the company has launched its GLP-1 agonist Byetta (exenatide) in China, and the drug will be in hospitals in first-tier cities by the end of September